REG - OptiBiotix Health - Director/PDMR Shareholding

OptiBiotix HealthAnnouncement

02/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251002:nRSB7141Ba&default-theme=true

RNS Number : 7141B  OptiBiotix Health PLC  02 October 2025

 

 

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Director/PDMR Shareholding

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes, announces that the Company has
been informed that David Blain, a Director of the Company, made the following
purchase of ordinary shares in the capital of the Company. Further details are
set out in the Notification of Dealing Form below.

 

 Director     Purchase price  Ordinary shares purchased  Resultant interest in ordinary shares  Resultant percentage of issued ordinary shares
 David Blain  11.75 pence     84,053                     84,053                                 0.08%

 

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                 www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)       Tel: 020 7213 0880
 Liam Murray / Ludovico Lazzaretti / James Western

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         David Blain
 2   Reason for notification
 a.  Position/Status                                              Finance Director
 b.  Initial notification/                                        Initial Notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         OptiBiotix Health Plc
 b.  LEI
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of 2p each

Identification Code

                                                                  ISIN: GB00BP0RTP38
 b.  Nature of the transaction                                    Purchase of ordinary shares

 c.  Price(s) and volume(s)
                                                                               Price(s) per share  Volume(s)
     11.75 pence                                                               84,053

 d.  Aggregated information

     -       Volume                                               84,053 shares

     -       Price                                                11.75 pence per share
 e.  Date of the transaction                                      1 October 2025
 f.  Place of the transaction                                     London Alternative Market (AIMX)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFSMFMFEISEDS